Accompanied by neurologic symptoms such as leg weakness, numbness, bowel or bladder dysfunction, or saddle anesthesiathese are red flags for cauda equina syndrome or severe nerve compression requiring emergency evaluation
Composition BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of BPC-157 and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of two co-formulated peptides Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions Documentation Lot-specific COA Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
They are approved based on proving equivalent efficacy and usually cost less than name-brand medications
What's New: July 2026 Update TRIUMPH-4 confirmed final: 28.7% weight loss at 68 weeks peer-reviewed data, December 2025 TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients
The main anthocyanin monomer from Lycium ruthenicum Murray fruit mediates obesity via modulating the gut microbiota and improving the intestinal barrier